Who We Are
Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.
The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world.
The company has an ever-growing global presence while at the same time remaining firmly rooted in its home market, Switzerland.
Vifor Pharma Group consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, its joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
Vifor Pharma Group Companies
Vifor Pharma is a a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Key brands in the iron treatment portfolio are intravenous products, Ferinject® and Venofer®, and oral product, Maltofer®.
Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is a common company of Vifor Pharma Group and Fresenius Medical Care. VFMCRP develops and commercialises innovative, high-quality therapies in nephrology to improve the lives of patients suffering from chronic kidney disease (CKD) worldwide. The company was founded at the end of 2010 and is owned 55% by Vifor Pharma Group (formerly Galenica Group) and 45% by Fresenius Medical Care.
As a leader in nephrology and partner of choice for renal pharmaceuticals, the company’s product portfolio is specialised in anaemia management (Venofer®, Ferinject®, Mircera®), mineral and bone management (Velphoro®, Rayaldee®, Osvaren®) and cardio-renal management (patiromer (US brand name: Veltassa®), Ferinject®). In addition, VFMCRP and its partner ChemoCentryx are building a presence in rare diseases by developing avacopan (CCX168) and CCX140.
US-based biopharmaceutical company Relypsa focuses on the discovery, development and commercialisation of polymeric medicines for patients with often overlooked and undertreated conditions that can be addressed in the gastrointestinal tract. Relypsa’s first product, Veltassa®, was made for treating hyperkalaemia. It is the first new medicine in more than 50 years for patients with elevated serum potassium. Relypsa became a Vifor Pharma company in 2016.
With its unique expertise in the field of immunology, OM Pharma develops and manufactures infectious diseases/OTX products for respiratory tract infections, lower urinary tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, chronic venous insufficiency, diabetic retinopathy, haemorrhoids, menometrorrhagia (heavy menstrual bleeding).
Its key brands are Broncho-Vaxom®, Dicynone®, Doxium® and Uro-Vaxom®, and they are excellent complements to ViforPharma Group’s other therapeutic areas. The potential of Broncho-Vaxom® and Uro-Vaxom® is of increasing medical interest as international health agencies and governments address the ongoing rise of antimicrobial resistance around the world.
These two treatments are made to help patients stave off recurrent infections and so to need fewer antibiotics.